Aspirin resistance: Is this term meaningful?

Current Opinion in Hematology

Volumn 13, Issue 5, 2006, Pages 331-336

  Violi, Francesco ^a   Pignatelli, Pasquale ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Aspirin resistance; Platelets; Thromboxane A2

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; THROMBOXANE A2;

ASPIRIN RESISTANCE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE RESISTANCE; DRUG EFFECT; DRUG MONITORING; DRUG SENSITIVITY; EX VIVO STUDY; HEART INFARCTION; HEART MUSCLE NECROSIS; HUMAN; ISCHEMIC HEART DISEASE; LABORATORY DIAGNOSIS; LABORATORY TEST; LONG TERM CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTOPOIESIS;

ASPIRIN; BLOOD PLATELETS; CYCLOOXYGENASE 1; DRUG RESISTANCE; HUMANS; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THROMBOXANE A2;

EID: 33746743027     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/01.moh.0000239704.17427.9b     Document Type: Review

References (39)

1. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101:1206-1218.
2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii:349-360.
3. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308:81-106.
4. Violi F, Pignatelli P, Pulcinelli FM. Aspirin. J Thromb Haemost 2004; 2:338-339.
5. Zimmermann N, Wenk A, Kim U, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108:542-547.
6. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345:1809-1817.
7. Mueller MR, Salat A, Stangl P, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78:1003-1007.
8. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88:230-235.
9. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105:1650-1655.
10. Ho WK, Hankey GJ, Eikelboom JW. Is there a role for laboratory testing to identify patients at risk of aspirin treatment failure? Blood Coagul Fibrinolysis 2004; 15:129-130.
11. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24:1980-1987.
12. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2005; 46:986-993.
13. Szczeklik A, Musial J, Undas A, Sanak M. Aspirin resistance. J Thromb Haemost 2005; 3:1655-1662.
14. Rocca B, Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 2005; 3:1597-1602.
15. Campbell CL, Steinhubl SR. Variability in response to aspirin: do we understand the clinical relevance? J Thromb Haemost 2005; 3:665-669.
16. Sanderson S, Emery J, Baglin T, Kinmonth AL. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 2005; 142:370-380.
17. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353:2373-2383.
18. Fateh-Moghadam S, Plockinger U, Cabeza N, et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 2005; 42:99-103.
19. Coma-Canella I, Velasco A, Castano S. Prevalence of aspirin resistance measured by PFA-100. Int J Cardiol 2005; 101:71-76.
20. Addad F, Hassine M, Ben Farhat M, et al. Intra-individual variability of the platelet antiaggregation effect of aspirin in coronary patients. Arch Mal Coeur Vaiss 2005; 98:979-983.
21. McCabe DJ, Harrison P, Mackie IJ, et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets 2005; 16:269-280.
22. Borna C, Lazarowski E, van Heusden C, et al. Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb J 2005; 3:10.
23. Gonzalez-Conejero R, Rivera J, Corral J, et al. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 2005; 36:276-280.
24. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005; 46:1705-1709. This study questions the existence of aspirin resistance because it demonstrates that in case of accurate analysis of compliance with aspirin therapy, ex-vivo tests of platelet activation are fully inhibited.
25. Lee PY, Chen WH, Ng W, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005; 118:723-727.
26. 2 after in-vitro addition of aspirin.
27. Eikelboom JW, Hankey GJ, Thom J, et al. Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. J Thromb Haemost 2005; 3:2649-2655.
28. 2 inhibited agonist-induced platelet aggregation.
29. Maree AO, Curtin RJ, Chubb A, et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005; 3:2340-2345. This study adds further insight into the mechanism leading to 'aspirin resistance' because it demonstrates that COX-1 polymorphism may render platelets less sensitive to aspirin.
30. Schwartz KA, Schwartz DE, Ghosheh K, et al. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005; 95:973-975. This study is relevant to the existence of 'aspirin resistance' because it demonstrates that platelet insensitivity to aspirin is no longer detectable when aspirin compliance is accurately determined.
31. Chen WH, Lee PY, Ng W, et al. Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention. Am J Cardiol 2000; 96:760-763.
32. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006; 47:27-33.
33. Pamukcu B, Oflaz H, Nisanci Y. The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis. Am Heart J 2005; 149:675-680.
34. Yilmaz MB, Balbay Y, Caldir V, et al. Late saphenous vein graft occlusion in patients with coronary bypass: possible role of aspirin resistance. Thromb Res 2005; 115:25-29.
35. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006; 27:647-654.
36. Lahoz C, Pena R, Mostaza JM, et al., RAP Study Group. The -514C/T polymorphism of the hepatic lipase gene significantly modulates the HDL-cholesterol response to statin treatment. Atherosclerosis 2000; 182:129-134.
37. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-153.
38. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
39. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502.